Castle Biosciences, Inc. (CSTL) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Castle Biosciences, Inc. (CSTL) Earnings Overview
As of June 23, 2026, Castle Biosciences, Inc. (CSTL) reported trailing twelve-month net income of -$13M, reflecting -233.9% year-over-year growth. The company earned $-0.43 per diluted share over the past four quarters, with a net profit margin of -7.0%.
Looking at the long-term picture, CSTL's historical earnings data spans multiple years. The company achieved its highest annual net income of $18M in fiscal 2024.
Castle Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NTRA (-$226M net income, -9.0% margin), EXAS (-$208M net income, -6.4% margin), VCYT ($88M net income, 12.8% margin), CSTL has outperformed on profitability metrics. Compare CSTL vs NTRA →
CSTL Earnings vs Peers
Earnings metrics vs comparable public companies
CSTL Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$24M | -232.4% | -$43M | $-0.83 | -7.0% | -12.4% |
| 2024 | $18M | +131.7% | $9M | $0.62 | 5.5% | 2.6% |
| 2023 | -$57M | +14.4% | -$68M | $-2.14 | -26.1% | -30.9% |
| 2022 | -$67M | -114.6% | -$73M | $-2.58 | -49.0% | -53.2% |
| 2021 | -$31M | -204.3% | -$40M | $-1.24 | -33.3% | -42.6% |
| 2020 | -$10M | -294.9% | -$7M | $-0.54 | -16.4% | -10.4% |
| 2019 | $5M | +182.9% | $7M | $-0.21 | 10.2% | 14.1% |
| 2018 | -$6M | +48.5% | -$4M | $-0.60 | -27.9% | -16.8% |
| 2017 | -$12M | - | -$11M | $-1.26 | -89.9% | -79.2% |
Download Data
Export CSTL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CSTL — Frequently Asked Questions
Quick answers to the most common questions about buying CSTL stock.
What is CSTL earnings per share (EPS)?
CSTL trailing twelve-month (TTM) diluted EPS is $-0.43, reflecting -233.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Castle Biosciences, Inc.'s net income?
Castle Biosciences, Inc. (CSTL) trailing twelve-month net income is $-13M as of 2025. Earnings declined -233.9% year-over-year.
Is CSTL profitable?
CSTL is not currently profitable on a TTM basis, reporting a net loss of $-13M. Net margin is -7.0%. Investors should monitor for a return to profitability.
What is CSTL's earnings growth rate?
CSTL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are CSTL's profit margins?
Castle Biosciences, Inc. net profit margin is -7.0%, operating margin is -12.4%, and gross margin is +79.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -5.2%.
Is CSTL growing earnings?
CSTL earnings are declining — EPS fell -233.9% year-over-year. TTM net income dropped to $-13M. This contrasts with the 5-year CAGR of N/A.
What was CSTL's best earnings year?
Castle Biosciences, Inc.'s highest annual net income on record is $18M, achieved in fiscal year 2024. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were CSTL's earnings last quarter?
CSTL's most recent reported quarter was Q1 2026. Net income was $-15M with diluted EPS of $-0.49. For a full breakdown of all quarters, see the quarterly earnings table on this page.